Article metrics

Download PDFPDF

Original article
Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort

 

Online download statistics by month:

Online download statistics by month: September 2016 to March 2024

AbstractFullPdf
Sep 2016889510448
Oct 20162624575566
Nov 20161315302454
Dec 201636115399
Jan 2017259177139
Feb 201765207112
Mar 2017128675
Apr 201766749
May 201736463
Jun 2017255545
Jul 2017555238
Aug 2017746853
Sep 2017626458
Oct 2017595939
Nov 2017797741
Dec 2017635333
Jan 20181209232
Feb 2018665415
Mar 2018888650
Apr 201810711129
May 2018575927
Jun 2018828039
Jul 2018686059
Aug 2018888835
Sep 2018696943
Oct 2018666423
Nov 2018646019
Dec 2018464617
Jan 2019988938
Feb 2019957625
Mar 2019816033
Apr 2019895621
May 2019905536
Jun 2019916022
Jul 2019896331
Aug 2019814720
Sep 2019856514
Oct 2019804621
Nov 2019484010
Dec 2019967834
Jan 2020504414
Feb 2020805717
Mar 2020786010
Apr 202049338
May 2020725922
Jun 202055517
Jul 2020745515
Aug 2020373313
Sep 2020605614
Oct 202057419
Nov 2020613719
Dec 2020553623
Jan 2021574513
Feb 202152426
Mar 2021544214
Apr 2021514214
May 202135346
Jun 202116616613
Jul 2021231812
Aug 202117166
Sep 2021252514
Oct 2021464017
Nov 2021483226
Dec 2021646018
Jan 2022958314
Feb 202266598
Mar 202258486
Apr 2022676015
May 2022766628
Jun 2022444010
Jul 2022372910
Aug 202252409
Sep 2022453915
Oct 2022332411
Nov 202248379
Dec 202220175
Jan 2023373014
Feb 202359476
Mar 202340368
Apr 202325157
May 202317137
Jun 202332185
Jul 2023271310
Aug 202314139
Sep 202362513
Oct 202312110411
Nov 202357535
Dec 2023101854
Jan 202433175
Feb 202432163
Mar 2024623021
Total1062163803593